Reducing the toxicity of the combined modality therapy of favourable stage Hodgkin's disease.
Rosenberg
S A
SA
Department of Medicine, Stanford University School of Medicine, CA 94305.
D000328:Adult; D002648:Child; D003131:Combined Modality Therapy / Q000009:adverse effects; D004334:Drug Administration Schedule; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D011879:Radiotherapy Dosage; D013156:Splenectomy / Q000009:adverse effects